Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002)

Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002)

Trial Category:
Genitourinary
Phase
I
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members